The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome.
Sarah Gabrielle Ellis
No relevant relationships to disclose
Matthew Wheater
No relevant relationships to disclose
Katherine Tier
No relevant relationships to disclose
Angelica Cazaly
No relevant relationships to disclose
James Smart
No relevant relationships to disclose
Jeffrey Theaker
No relevant relationships to disclose
Henry Hepburne-Scott
Employment or Leadership Position - Serametrix Corporation
Stock Ownership - Serametrix Corporation
Phoebe Bonner-Ferraby
Employment or Leadership Position - Serametrix Corporation
Christian H.H Ottensmeier
No relevant relationships to disclose